MEI Pharma Reports Initial Data From Clinical Study Evaluating Me-344 in Combination With Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma報告了評估Me-344與貝伐珠單抗(阿瓦斯汀®)聯合治療復發轉移性結直腸癌患者的臨床研究的初步數據
MEI Pharma Reports Initial Data From Clinical Study Evaluating Me-344 in Combination With Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma報告了評估Me-344與貝伐珠單抗(阿瓦斯汀®)聯合治療復發轉移性結直腸癌患者的臨床研究的初步數據
使用瀏覽器的分享功能,分享給你的好友吧